Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo

Bristol Myers Squibb Announces Phase III Results Exploring the Potential of Opdivo

Source: 
BioSpace
snippet: 

Bristol Myers Squibb announced today that its Phase III CheckMate -816 trial met its primary endpoint of pathologic complete response (pCR) in patients with resectable non-small cell lung cancer. The subjects who received Opdivo (nivolumab) along with chemotherapy before surgery showed no evidence of cancer cells in their resected tissue. This was compared to individuals who received chemotherapy alone.